495 related articles for article (PubMed ID: 29357840)
1. FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-X
Maciel-Silva P; Caldeira I; de Assis Santos I; Carreira ACO; Siqueira FR; Antonioli E; Goldberg AC; Belizário JE; Garay-Malpartida HM
BMC Cancer; 2018 Jan; 18(1):90. PubMed ID: 29357840
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
Ogura T; Tanaka Y; Tamaki H; Harada M
Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of FAM3B triggers cell apoptosis through p53-dependent pathway.
Mou H; Li Z; Yao P; Zhuo S; Luan W; Deng B; Qian L; Yang M; Mei H; Le Y
Int J Biochem Cell Biol; 2013 Mar; 45(3):684-91. PubMed ID: 23246487
[TBL] [Abstract][Full Text] [Related]
5. FAM3B promotes progression of oesophageal carcinoma via regulating the AKT-MDM2-p53 signalling axis and the epithelial-mesenchymal transition.
He SL; Wang WP; Yang YS; Li EM; Xu LY; Chen LQ
J Cell Mol Med; 2019 Feb; 23(2):1375-1385. PubMed ID: 30565387
[TBL] [Abstract][Full Text] [Related]
6. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins.
Tang DG; Li L; Chopra DP; Porter AT
Cancer Res; 1998 Aug; 58(15):3466-79. PubMed ID: 9699682
[TBL] [Abstract][Full Text] [Related]
7. Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.
Vilenchik M; Raffo AJ; Benimetskaya L; Shames D; Stein CA
Cancer Res; 2002 Apr; 62(7):2175-83. PubMed ID: 11929841
[TBL] [Abstract][Full Text] [Related]
8. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
Hu H; Li GX; Wang L; Watts J; Combs GF; Lü J
Clin Cancer Res; 2008 Feb; 14(4):1150-8. PubMed ID: 18281549
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis in prostatic tumor cell line DU145 by staurosporine, a potent inhibitor of protein kinases.
Zhang H; Hoang T; Saeed B; Ng SC
Prostate; 1996 Aug; 29(2):69-76. PubMed ID: 8700802
[TBL] [Abstract][Full Text] [Related]
11. Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice.
Pirtskhalaishvili G; Shurin GV; Gambotto A; Esche C; Wahl M; Yurkovetsky ZR; Robbins PD; Shurin MR
J Immunol; 2000 Aug; 165(4):1956-64. PubMed ID: 10925278
[TBL] [Abstract][Full Text] [Related]
12. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak.
Castilla C; Congregado B; Chinchón D; Torrubia FJ; Japón MA; Sáez C
Endocrinology; 2006 Oct; 147(10):4960-7. PubMed ID: 16794010
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer.
Li X; Marani M; Yu J; Nan B; Roth JA; Kagawa S; Fang B; Denner L; Marcelli M
Cancer Res; 2001 Jan; 61(1):186-91. PubMed ID: 11196158
[TBL] [Abstract][Full Text] [Related]
15. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
16. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
17. Influence of Bax or Bcl-2 overexpression on the ceramide-dependent apoptotic pathway in glioma cells.
Sawada M; Nakashima S; Banno Y; Yamakawa H; Takenaka K; Shinoda J; Nishimura Y; Sakai N; Nozawa Y
Oncogene; 2000 Jul; 19(31):3508-20. PubMed ID: 10918609
[TBL] [Abstract][Full Text] [Related]
18. Functional and biological analysis of Bcl-xL expression in human osteosarcoma.
Wang ZX; Yang JS; Pan X; Wang JR; Li J; Yin YM; De W
Bone; 2010 Aug; 47(2):445-54. PubMed ID: 20580954
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines.
Karaca B; Degirmenci M; Ozveren A; Atmaca H; Bozkurt E; Karabulut B; Sanli UA; Uslu R
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1273-80. PubMed ID: 25925002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
